Amarantus Bioscience Holdings Inc (AMBS)

[brharris]

Based on you comment #1 there is no point in reading the rest of your post. That is not what the company said.

To this end, the Board of Directors has given management the mandate to accelerate our partnering initiatives in order to acquire the resources necessary to move the rest of the portfolio forward. Given the diversity and robustness of our rich clinical pipeline, many options exist to best execute on this directive while preserving and/or transferring value to our shareholders along the way. The Company had previously made the decision to transact on the diagnostics portfolio in order to become a pure-play therapeutics company. We will likely take this approach one step further and also seek to transact on either ESS or Eltoprazine in order to further refine the Company’s profile into a regenerative medicine company (ESS + MANF + Phenoguard) or a neurology company (Eltoprazine + MANF + Phenoguard), and achieve economic benefit from such a transaction. In looking at the pipeline, it is critical to note the late stage nature of ESS and Eltoprazine; each of these assets, individually, could provide a pipeline for a very valuable standalone public company.